Influence of CYP2C19 Polymorphisms on the Pharmacokinetics of Omeprazole in Elderly Subjects
Omeprazole blocks the gastric H+/K+ adenosine triphosphatase, thus inhibiting gastric acid secretion, and is metabolized by cytochrome P450 (CYP) 2C19. Due to the physiological changes in the elderly, there are different pharmacokinetic consequences compared to young people. The aim of this study wa...
Saved in:
| Published in | Clinical pharmacology in drug development Vol. 10; no. 12; pp. 1469 - 1477 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wiley Subscription Services, Inc
01.12.2021
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 2160-763X 2160-7648 2160-7648 |
| DOI | 10.1002/cpdd.966 |
Cover
Loading…
| Abstract | Omeprazole blocks the gastric H+/K+ adenosine triphosphatase, thus inhibiting gastric acid secretion, and is metabolized by cytochrome P450 (CYP) 2C19. Due to the physiological changes in the elderly, there are different pharmacokinetic consequences compared to young people. The aim of this study was to evaluate the pharmacokinetic profiles of omeprazole in 15 elderly participants according to the CYP2C19 genotype. The concentration‐time profiles of omeprazole and its metabolites, 5‐hydroxy (5‐OH) omeprazole and omeprazole sulfone, were similar between the CYP2C19 extensive metabolizer (EM) and intermediate metabolizer groups. In contrast, when comparing the EM group and CYP2C19 poor metabolizer (PM) group, the EM/PM geometric mean ratio (95% confidence interval) of area under the plasma concentration–time curve from time of dosing to the last measurable concentration was 0.52 (0.27‐1.01) and that of the IM group was 0.71 (0.32‐1.59), indicating that the exposure of omeprazole in the PM group was increased. The exposure of 5‐OH omeprazole was significantly decreased in the PM group when compared to the EM group, with an EM/PM geometric mean ratio (95% confidence interval) of 2.20 (1.50‐3.22). In conclusion, the tendency of drug exposure according to the CYP2C19 genotype in the elderly and young adults was similar in that the exposure level was highest in the PM group. However, when compared to young adults, the difference between the genotype groups was smaller in the elderly. |
|---|---|
| AbstractList | Omeprazole blocks the gastric H+ /K+ adenosine triphosphatase, thus inhibiting gastric acid secretion, and is metabolized by cytochrome P450 (CYP) 2C19. Due to the physiological changes in the elderly, there are different pharmacokinetic consequences compared to young people. The aim of this study was to evaluate the pharmacokinetic profiles of omeprazole in 15 elderly participants according to the CYP2C19 genotype. The concentration-time profiles of omeprazole and its metabolites, 5-hydroxy (5-OH) omeprazole and omeprazole sulfone, were similar between the CYP2C19 extensive metabolizer (EM) and intermediate metabolizer groups. In contrast, when comparing the EM group and CYP2C19 poor metabolizer (PM) group, the EM/PM geometric mean ratio (95% confidence interval) of area under the plasma concentration-time curve from time of dosing to the last measurable concentration was 0.52 (0.27-1.01) and that of the IM group was 0.71 (0.32-1.59), indicating that the exposure of omeprazole in the PM group was increased. The exposure of 5-OH omeprazole was significantly decreased in the PM group when compared to the EM group, with an EM/PM geometric mean ratio (95% confidence interval) of 2.20 (1.50-3.22). In conclusion, the tendency of drug exposure according to the CYP2C19 genotype in the elderly and young adults was similar in that the exposure level was highest in the PM group. However, when compared to young adults, the difference between the genotype groups was smaller in the elderly.Omeprazole blocks the gastric H+ /K+ adenosine triphosphatase, thus inhibiting gastric acid secretion, and is metabolized by cytochrome P450 (CYP) 2C19. Due to the physiological changes in the elderly, there are different pharmacokinetic consequences compared to young people. The aim of this study was to evaluate the pharmacokinetic profiles of omeprazole in 15 elderly participants according to the CYP2C19 genotype. The concentration-time profiles of omeprazole and its metabolites, 5-hydroxy (5-OH) omeprazole and omeprazole sulfone, were similar between the CYP2C19 extensive metabolizer (EM) and intermediate metabolizer groups. In contrast, when comparing the EM group and CYP2C19 poor metabolizer (PM) group, the EM/PM geometric mean ratio (95% confidence interval) of area under the plasma concentration-time curve from time of dosing to the last measurable concentration was 0.52 (0.27-1.01) and that of the IM group was 0.71 (0.32-1.59), indicating that the exposure of omeprazole in the PM group was increased. The exposure of 5-OH omeprazole was significantly decreased in the PM group when compared to the EM group, with an EM/PM geometric mean ratio (95% confidence interval) of 2.20 (1.50-3.22). In conclusion, the tendency of drug exposure according to the CYP2C19 genotype in the elderly and young adults was similar in that the exposure level was highest in the PM group. However, when compared to young adults, the difference between the genotype groups was smaller in the elderly. Omeprazole blocks the gastric H+/K+ adenosine triphosphatase, thus inhibiting gastric acid secretion, and is metabolized by cytochrome P450 (CYP) 2C19. Due to the physiological changes in the elderly, there are different pharmacokinetic consequences compared to young people. The aim of this study was to evaluate the pharmacokinetic profiles of omeprazole in 15 elderly participants according to the CYP2C19 genotype. The concentration‐time profiles of omeprazole and its metabolites, 5‐hydroxy (5‐OH) omeprazole and omeprazole sulfone, were similar between the CYP2C19 extensive metabolizer (EM) and intermediate metabolizer groups. In contrast, when comparing the EM group and CYP2C19 poor metabolizer (PM) group, the EM/PM geometric mean ratio (95% confidence interval) of area under the plasma concentration–time curve from time of dosing to the last measurable concentration was 0.52 (0.27‐1.01) and that of the IM group was 0.71 (0.32‐1.59), indicating that the exposure of omeprazole in the PM group was increased. The exposure of 5‐OH omeprazole was significantly decreased in the PM group when compared to the EM group, with an EM/PM geometric mean ratio (95% confidence interval) of 2.20 (1.50‐3.22). In conclusion, the tendency of drug exposure according to the CYP2C19 genotype in the elderly and young adults was similar in that the exposure level was highest in the PM group. However, when compared to young adults, the difference between the genotype groups was smaller in the elderly. Omeprazole blocks the gastric H + /K + adenosine triphosphatase, thus inhibiting gastric acid secretion, and is metabolized by cytochrome P450 (CYP) 2C19. Due to the physiological changes in the elderly, there are different pharmacokinetic consequences compared to young people. The aim of this study was to evaluate the pharmacokinetic profiles of omeprazole in 15 elderly participants according to the CYP2C19 genotype. The concentration‐time profiles of omeprazole and its metabolites, 5‐hydroxy (5‐OH) omeprazole and omeprazole sulfone, were similar between the CYP2C19 extensive metabolizer (EM) and intermediate metabolizer groups. In contrast, when comparing the EM group and CYP2C19 poor metabolizer (PM) group, the EM/PM geometric mean ratio (95% confidence interval) of area under the plasma concentration–time curve from time of dosing to the last measurable concentration was 0.52 (0.27‐1.01) and that of the IM group was 0.71 (0.32‐1.59), indicating that the exposure of omeprazole in the PM group was increased. The exposure of 5‐OH omeprazole was significantly decreased in the PM group when compared to the EM group, with an EM/PM geometric mean ratio (95% confidence interval) of 2.20 (1.50‐3.22). In conclusion, the tendency of drug exposure according to the CYP2C19 genotype in the elderly and young adults was similar in that the exposure level was highest in the PM group. However, when compared to young adults, the difference between the genotype groups was smaller in the elderly. Omeprazole blocks the gastric H+/K+ adenosine triphosphatase, thus inhibiting gastric acid secretion, and is metabolized by cytochrome P450 (CYP) 2C19. Due to the physiological changes in the elderly, there are different pharmacokinetic consequences compared to young people. The aim of this study was to evaluate the pharmacokinetic profiles of omeprazole in 15 elderly participants according to the CYP2C19 genotype. The concentration‐time profiles of omeprazole and its metabolites, 5‐hydroxy (5‐OH) omeprazole and omeprazole sulfone, were similar between the CYP2C19 extensive metabolizer (EM) and intermediate metabolizer groups. In contrast, when comparing the EM group and CYP2C19 poor metabolizer (PM) group, the EM/PM geometric mean ratio (95% confidence interval) of area under the plasma concentration–time curve from time of dosing to the last measurable concentration was 0.52 (0.27‐1.01) and that of the IM group was 0.71 (0.32‐1.59), indicating that the exposure of omeprazole in the PM group was increased. The exposure of 5‐OH omeprazole was significantly decreased in the PM group when compared to the EM group, with an EM/PM geometric mean ratio (95% confidence interval) of 2.20 (1.50‐3.22). In conclusion, the tendency of drug exposure according to the CYP2C19 genotype in the elderly and young adults was similar in that the exposure level was highest in the PM group. However, when compared to young adults, the difference between the genotype groups was smaller in the elderly. Omeprazole blocks the gastric H /K adenosine triphosphatase, thus inhibiting gastric acid secretion, and is metabolized by cytochrome P450 (CYP) 2C19. Due to the physiological changes in the elderly, there are different pharmacokinetic consequences compared to young people. The aim of this study was to evaluate the pharmacokinetic profiles of omeprazole in 15 elderly participants according to the CYP2C19 genotype. The concentration-time profiles of omeprazole and its metabolites, 5-hydroxy (5-OH) omeprazole and omeprazole sulfone, were similar between the CYP2C19 extensive metabolizer (EM) and intermediate metabolizer groups. In contrast, when comparing the EM group and CYP2C19 poor metabolizer (PM) group, the EM/PM geometric mean ratio (95% confidence interval) of area under the plasma concentration-time curve from time of dosing to the last measurable concentration was 0.52 (0.27-1.01) and that of the IM group was 0.71 (0.32-1.59), indicating that the exposure of omeprazole in the PM group was increased. The exposure of 5-OH omeprazole was significantly decreased in the PM group when compared to the EM group, with an EM/PM geometric mean ratio (95% confidence interval) of 2.20 (1.50-3.22). In conclusion, the tendency of drug exposure according to the CYP2C19 genotype in the elderly and young adults was similar in that the exposure level was highest in the PM group. However, when compared to young adults, the difference between the genotype groups was smaller in the elderly. |
| Author | Na, Joo Young Chung, Jae‐Yong Yoon, Jangsoo Choi, Yewon Yoon, Seo Hyun Yu, Kyung‐Sang Jeon, Inseung |
| Author_xml | – sequence: 1 givenname: Joo Young surname: Na fullname: Na, Joo Young organization: Seoul National University College of Medicine and Hospital – sequence: 2 givenname: Inseung surname: Jeon fullname: Jeon, Inseung organization: Seoul National University College of Medicine and Hospital – sequence: 3 givenname: Jangsoo surname: Yoon fullname: Yoon, Jangsoo organization: Seoul National University College of Medicine and Hospital – sequence: 4 givenname: Yewon surname: Choi fullname: Choi, Yewon organization: Genosco Inc – sequence: 5 givenname: Seo Hyun surname: Yoon fullname: Yoon, Seo Hyun organization: Seoul National University College of Medicine and Hospital – sequence: 6 givenname: Kyung‐Sang surname: Yu fullname: Yu, Kyung‐Sang organization: Seoul National University College of Medicine and Hospital – sequence: 7 givenname: Jae‐Yong surname: Chung fullname: Chung, Jae‐Yong email: jychung@snubh.org organization: Seoul National University College of Medicine and Bundang Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34337876$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kdtq3DAQhkVJaA4N9AmKoTe58VYnS_JlcdI0EMhCW2ihIGR5zGorS65kUzZPHy9JUwjN3MzAfP_MMP8JOggxAEJvCV4RjOkHO3bdqhbiFTqmROBSCq4Onmr2_Qid5bzFSwhMCOGv0RHjjEklxTH6eR16P0OwUMS-aH6saUPqYh39bohp3Lg85CKGYtpAsd6YNBgbf7kAk7N5L7gdYEzmLnooXCgufQfJ74ovc7sFO-U36LA3PsPZYz5F3z5dfm0-lze3V9fNx5vSclKJsuWG1hYzrlpCMatMJwiuMZO8Za2slK1bpTiXAojtCVSKVbRTSwswA8kFO0XnD3PHFH_PkCc9uGzBexMgzlnTqpIVp1SyBX3_DN3GOYXlOk0FVlQSqeqFevdIze0AnR6TG0za6b9_-7fRpphzgv4JIVjvXdF7V_TiyoKunqHWTWZyMUzJOP8_Qfkg-OM87F4crJv1xcWevwcA9ZqW |
| CitedBy_id | crossref_primary_10_2147_PGPM_S371994 crossref_primary_10_1007_s12272_022_01423_0 crossref_primary_10_1002_cpt_3183 crossref_primary_10_1161_JAHA_123_032248 crossref_primary_10_1007_s40266_024_01117_w |
| Cites_doi | 10.1080/03602530902722679 10.1038/clpt.2009.1 10.2165/00003088-200544010-00002 10.1093/gerona/glr118 10.1056/NEJM198205063061804 10.1081/DMR-120023681 10.2133/dmpk.20.153 10.1038/tpj.2012.10 10.1016/j.jsps.2018.05.009 10.2165/11531320-000000000-00000 10.3346/jkms.2017.32.5.729 10.1002/hep.1840090222 10.1517/phgs.5.2.181.27483 10.1111/j.1365-2036.2004.02120.x 10.2146/ajhp050490 10.2165/00003088-199223060-00006 10.1007/BF03189822 10.1053/gast.2000.16515 10.1016/j.phrs.2019.104606 10.1038/s41598-019-55562-4 10.2165/00003088-199324010-00006 10.3109/00365528909091241 10.1208/s12249-015-0365-2 10.2165/00003088-200544110-00005 |
| ContentType | Journal Article |
| Copyright | 2021, The American College of Clinical Pharmacology 2021, The American College of Clinical Pharmacology. American College of Clinical Pharmacology |
| Copyright_xml | – notice: 2021, The American College of Clinical Pharmacology – notice: 2021, The American College of Clinical Pharmacology. – notice: American College of Clinical Pharmacology |
| DBID | AAYXX CITATION NPM K9. 7X8 |
| DOI | 10.1002/cpdd.966 |
| DatabaseName | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) CrossRef PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 2160-7648 |
| EndPage | 1477 |
| ExternalDocumentID | 34337876 10_1002_cpdd_966 CPDD966 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | -MK 05W 0R~ 1OC 33P 3SF 52U 52V 53G 8-1 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AAXRX AAYCA AAZKR ABCUV ABDBF ABJNI ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACRPL ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUYR AFBPY AFFPM AFGKR AFPWT AFWVQ AHBTC AIACR AITYG AIURR AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZFZN AZVAB BDRZF BFHJK BHBCM BMXJE BNHUX BOGZA BRXPI C45 DCZOG DPXWK DRFUL DRMAN DRSTM EBS EJD FUBAC G-S GODZA H13 HGLYW KBYEO LATKE LEEKS LH4 LITHE LOXES LSO LUTES LW6 LYRES MEWTI MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ O66 O9- OVD P2W PQQKQ R.K ROL SUPJJ TEORI TUS WBKPD WIH WIJ WIK WOHZO WOIKV WPGGZ WXSBR WYJ ZZTAW AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION NPM AAMMB AEFGJ AGXDD AIDQK AIDYY K9. 7X8 |
| ID | FETCH-LOGICAL-c4156-b4a29c0348b12035ad61090374b3b758c9b884476e1cf1e58352d83b7e03e7463 |
| ISSN | 2160-763X 2160-7648 |
| IngestDate | Thu Jul 10 17:38:11 EDT 2025 Fri Jul 25 08:02:23 EDT 2025 Wed Feb 19 02:26:38 EST 2025 Thu Apr 24 22:58:26 EDT 2025 Tue Jul 01 00:19:13 EDT 2025 Wed Jan 22 16:28:33 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | omeprazole polymorphism pharmacogenomic CYP2C19 pharmacokinetic elderly |
| Language | English |
| License | 2021, The American College of Clinical Pharmacology. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c4156-b4a29c0348b12035ad61090374b3b758c9b884476e1cf1e58352d83b7e03e7463 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| PMID | 34337876 |
| PQID | 2608271789 |
| PQPubID | 2034576 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_2557542273 proquest_journals_2608271789 pubmed_primary_34337876 crossref_primary_10_1002_cpdd_966 crossref_citationtrail_10_1002_cpdd_966 wiley_primary_10_1002_cpdd_966_CPDD966 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | December 2021 |
| PublicationDateYYYYMMDD | 2021-12-01 |
| PublicationDate_xml | – month: 12 year: 2021 text: December 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Oxford |
| PublicationTitle | Clinical pharmacology in drug development |
| PublicationTitleAlternate | Clin Pharmacol Drug Dev |
| PublicationYear | 2021 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 1993; 24 2004; 20 2019; 9 2009; 85 2010; 49 2009; 41 1982; 306 2012 2020; 152 2013; 13 2017; 32 2000; 119 1989; 9 1989; 166 2003; 35 2005; 20 2004; 5 2012; 67A 2007; 64 2016; 17 1992; 23 1998; 23 2005; 44 2018; 26 e_1_2_10_23_1 e_1_2_10_21_1 e_1_2_10_22_1 e_1_2_10_20_1 e_1_2_10_2_1 e_1_2_10_4_1 e_1_2_10_18_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_6_1 e_1_2_10_16_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_7_1 e_1_2_10_15_1 e_1_2_10_12_1 e_1_2_10_9_1 e_1_2_10_13_1 e_1_2_10_10_1 e_1_2_10_11_1 Dean L (e_1_2_10_24_1) 2012 e_1_2_10_25_1 e_1_2_10_26_1 |
| References_xml | – volume: 26 start-page: 1012 issue: 7 year: 2018 end-page: 1021 article-title: The use of proton pump inhibitors among older adults with intellectual disability: a cross sectional observational study publication-title: Saudi Pharma J – volume: 23 start-page: 469 issue: 6 year: 1992 end-page: 476 article-title: Pharmacokinetic study of omeprazole in elderly healthy volunteers publication-title: Clin Pharmacokinet – volume: 64 start-page: 166 issue: 2 year: 2007 end-page: 175 article-title: Identifying drugs needing pharmacogenetic monitoring in a Korean hospital publication-title: Am J Health‐Syst Pharm – volume: 13 start-page: 369 issue: 4 year: 2013 end-page: 377 article-title: Multi‐ethnic distribution of clinically relevant CYP2C genotypes and haplotypes publication-title: Pharmacogenomics J – volume: 35 start-page: 99 issue: 2‐3 year: 2003 end-page: 106 article-title: PM frequencies of major CYPs in Asians and Caucasians publication-title: Drug Metab Rev – volume: 41 start-page: 67 issue: 2 year: 2009 end-page: 76 article-title: Pharmacokinetics and drug metabolism in the elderly publication-title: Drug Metab Rev – volume: 5 start-page: 181 issue: 2 year: 2004 end-page: 202 article-title: Pharmacogenomics of proton pump inhibitors publication-title: Pharmacogenomics – volume: 20 start-page: 153 issue: 3 year: 2005 end-page: 167 article-title: Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor‐based therapies publication-title: Drug Metab Pharmacokinet – volume: 44 start-page: 33 issue: 1 year: 2005 end-page: 60 article-title: The influence of age and sex on the clearance of cytochrome P450 3A substrates publication-title: Clin Pharmacokinet – volume: 152 year: 2020 article-title: Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors publication-title: Pharmacol Res – volume: 306 start-page: 1081 issue: 18 year: 1982 end-page: 1088 article-title: Drug disposition in old age publication-title: N Engl J Med – year: 2012 – volume: 17 start-page: 418 issue: 2 year: 2016 end-page: 426 article-title: pH‐dependent solubility and dissolution behavior of carvedilol—case example of a weakly basic BCS class II drug publication-title: AAPS PharmSciTech – volume: 32 start-page: 729 issue: 5 year: 2017 end-page: 736 article-title: Effects of CYP2C19 genetic polymorphisms on PK/PD responses of omeprazole in Korean healthy volunteers publication-title: J Korean Med Sci – volume: 49 start-page: 509 issue: 8 year: 2010 end-page: 533 article-title: Drug‐drug interaction profiles of proton pump inhibitors publication-title: Clin Pharmacokinet – volume: 20 start-page: 577 issue: 5 year: 2004 end-page: 583 article-title: Use of anti‐secretory medication: a population‐based cohort study publication-title: Aliment Pharmacol Ther – volume: 166 start-page: 33 year: 1989 end-page: 40 article-title: Omeprazole: pharmacokinetics and metabolism in man publication-title: Scand J Gastroenterol Suppl – volume: 85 start-page: 431 issue: 4 year: 2009 end-page: 433 article-title: Variability in response to medicines in older people: phenotypic and genotypic factors publication-title: Clin Pharmacol Ther – volume: 9 issue: 1 year: 2019 article-title: Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects publication-title: Sci Rep – volume: 9 start-page: 297 issue: 2 year: 1989 end-page: 301 article-title: The effect of age upon liver volume and apparent liver blood flow in healthy man publication-title: Hepatology – volume: 119 start-page: 670 issue: 3 year: 2000 end-page: 676 article-title: Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism publication-title: Gastroenterology – volume: 67A start-page: 175 issue: 2 year: 2012 end-page: 180 article-title: Drug metabolism in older people—a key consideration in achieving optimal outcomes with medicines publication-title: J Gerontol Series A – volume: 44 start-page: 1179 issue: 11 year: 2005 end-page: 1189 article-title: The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics publication-title: Clin Pharmacokinet – volume: 24 start-page: 71 issue: 1 year: 1993 end-page: 78 article-title: Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis publication-title: Clin Pharmacokinet – volume: 23 start-page: 19 issue: 1 year: 1998 end-page: 26 article-title: Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans publication-title: Eur J Drug Metab Pharmacokinet – ident: e_1_2_10_15_1 doi: 10.1080/03602530902722679 – ident: e_1_2_10_11_1 doi: 10.1038/clpt.2009.1 – ident: e_1_2_10_13_1 doi: 10.2165/00003088-200544010-00002 – ident: e_1_2_10_18_1 doi: 10.1093/gerona/glr118 – volume-title: Medical Genetics Summaries year: 2012 ident: e_1_2_10_24_1 – ident: e_1_2_10_10_1 doi: 10.1056/NEJM198205063061804 – ident: e_1_2_10_7_1 doi: 10.1081/DMR-120023681 – ident: e_1_2_10_5_1 doi: 10.2133/dmpk.20.153 – ident: e_1_2_10_9_1 doi: 10.1038/tpj.2012.10 – ident: e_1_2_10_16_1 doi: 10.1016/j.jsps.2018.05.009 – ident: e_1_2_10_14_1 doi: 10.2165/11531320-000000000-00000 – ident: e_1_2_10_22_1 doi: 10.3346/jkms.2017.32.5.729 – ident: e_1_2_10_12_1 doi: 10.1002/hep.1840090222 – ident: e_1_2_10_23_1 doi: 10.1517/phgs.5.2.181.27483 – ident: e_1_2_10_17_1 doi: 10.1111/j.1365-2036.2004.02120.x – ident: e_1_2_10_8_1 doi: 10.2146/ajhp050490 – ident: e_1_2_10_20_1 doi: 10.2165/00003088-199223060-00006 – ident: e_1_2_10_2_1 doi: 10.1007/BF03189822 – ident: e_1_2_10_4_1 doi: 10.1053/gast.2000.16515 – ident: e_1_2_10_6_1 doi: 10.1016/j.phrs.2019.104606 – ident: e_1_2_10_21_1 doi: 10.1038/s41598-019-55562-4 – ident: e_1_2_10_25_1 doi: 10.2165/00003088-199324010-00006 – ident: e_1_2_10_3_1 doi: 10.3109/00365528909091241 – ident: e_1_2_10_26_1 doi: 10.1208/s12249-015-0365-2 – ident: e_1_2_10_19_1 doi: 10.2165/00003088-200544110-00005 |
| SSID | ssj0000601114 |
| Score | 2.2393079 |
| Snippet | Omeprazole blocks the gastric H+/K+ adenosine triphosphatase, thus inhibiting gastric acid secretion, and is metabolized by cytochrome P450 (CYP) 2C19. Due to... Omeprazole blocks the gastric H + /K + adenosine triphosphatase, thus inhibiting gastric acid secretion, and is metabolized by cytochrome P450 (CYP) 2C19. Due... Omeprazole blocks the gastric H /K adenosine triphosphatase, thus inhibiting gastric acid secretion, and is metabolized by cytochrome P450 (CYP) 2C19. Due to... Omeprazole blocks the gastric H+/K+ adenosine triphosphatase, thus inhibiting gastric acid secretion, and is metabolized by cytochrome P450 (CYP) 2C19. Due to... Omeprazole blocks the gastric H+ /K+ adenosine triphosphatase, thus inhibiting gastric acid secretion, and is metabolized by cytochrome P450 (CYP) 2C19. Due to... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1469 |
| SubjectTerms | Adenosine triphosphatase Confidence intervals CYP2C19 elderly Genotype & phenotype omeprazole pharmacogenomic pharmacokinetic Pharmacokinetics polymorphism Young adults |
| Title | Influence of CYP2C19 Polymorphisms on the Pharmacokinetics of Omeprazole in Elderly Subjects |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcpdd.966 https://www.ncbi.nlm.nih.gov/pubmed/34337876 https://www.proquest.com/docview/2608271789 https://www.proquest.com/docview/2557542273 |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdbCqMvY99L2w0NRvaQurPlL_mxTVq6wro8pNDAwMi2XMIay8QJY_3rd5Il2-lS2PbiBH2Cf6fznXT3E0If05yGKXxKrJAmieWFLrckybo8LmSM2NRjimf262VwfuVdXPvX7Ya-yi5ZJUfp3da8kv9BFcoAV5kl-w_INoNCAfwHfOEJCMPzrzD-Ym4YUUEVswkZOZGMaAN_Hl7fvFqYs4DhRDNU_wCjUhEzQ4dvC14u2Z0ML5wXw1N5Xfet0iRya6bqWq0jkz5ZtkTXKl8wW65vTN5VN4Tmso7AFWKotEkTpsN1ollR8U7xTNTFF6y4qYRoIw6ECjWY8Z9advTuBHE6kR5caTHiBLYVBjWdZqNy7a5okY4CBcUdbdXsNVNsWmbZUVTf09IBuFwohF3PdUEB3aPW1h_ruuox2iHgUNg9tHN8Mj45a_bjJC8N-IaGn9gmn81cu-iJ6b1pvPzhkWw6OMpCmT5DT7VrgY9rOXmOHvHiBRpo5H8d4mmbalcd4gGedMB8ib43woRFjrUw4Q1hwqLAIEz4vjDJDq0w4XmBtTBhI0yv0NXZ6XR0bumrN6xUevRWAms0Sm3Xo4lDbNdnmaTll1xFiZuAi5lGCaWeFwbcSXOH-9KOzyhUcdvloRe4r1GvEAV_izCJcjfPI0IcxrycBhFhDsltEvk-BXXA-uiTeadxqnnp5fUot3HNqE1iCUQMQPTRh6ZlWXOxbGlzYGCJ9UqtYvDZKQmdkEYwRFMNelQejrGCizW08X15GTRY8330poazmcTA30cDhe-Ds8ejyXgMv3sPDrGPdttlcoB6q-WavwOzdpW81xL5GyeQot4 |
| linkProvider | EBSCOhost |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Influence+of+CYP2C19+Polymorphisms+on+the+Pharmacokinetics+of+Omeprazole+in+Elderly+Subjects&rft.jtitle=Clinical+pharmacology+in+drug+development&rft.au=Na%2C+Joo+Young&rft.au=Jeon%2C+Inseung&rft.au=Yoon%2C+Jangsoo&rft.au=Choi%2C+Yewon&rft.date=2021-12-01&rft.eissn=2160-7648&rft.volume=10&rft.issue=12&rft.spage=1469&rft_id=info:doi/10.1002%2Fcpdd.966&rft_id=info%3Apmid%2F34337876&rft.externalDocID=34337876 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2160-763X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2160-763X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2160-763X&client=summon |